ELETRIPTAN MARKET

INTRODUCTION

El triptan is a second-generation triptan drug used to treat migraine headaches. It is marketed under the brand name Relax and comes in the form of El triptan hydrobromide. It serves as an abortive drug, stopping an already-in-progress migraine headache.

Treatment for migraine headache symptoms with El triptan (severe throbbing headaches that sometimes are accompanied by nausea and sensitivity to sound and light). El triptan belongs to the group of drugs known as selective serotonin receptor agonists.

It eases pain, nausea, vomiting, and other migraine symptoms, such as sensitivity to light and sound. El triptan use for ten or more days each month, whether alone or in conjunction with other migraine medications, may exacerbate headaches. 

ELETRIPTAN MARKET SIZE AND FORECAST

The Global El triptan Market accounted for $XX Billion in 2023 and is anticipated to reach $XX Billion by 2030, registering a CAGR of XX% from 2024 to 2030.

ELETRIPTAN MARKET RECENT DEVELOPMENT

The most recent "triptan" to be authorized for the treatment of migraine headaches is El triptan. It is the sixth company to enter this competitive market. Pfizer will market "Relax" as El triptan, a selective 5-hydroxytryptamine (serotonin) 1B/1D receptor (5-HT1B, 5-HT1D) agonist.

Adults suffering from acute migraine with or without aura should take El triptan. El triptan has a strong bioavailability of 50%, a high lipid solubility, and a good elimination half-life of 4-6 hours. It also has a sluggish rate of dissociation from 5-HT1D receptors and a very low affinity for HT2 receptors in coronary arteries.

At two hours, El triptan was said to have a better response than sumatriptan. In comparison to sumatriptan (40–80 mg), El triptan (40–80 mg) produced headache responses ranging from 64-67% to 50–53%. (50 mg-100 mg). Both 19-18% and 31-37% of respondents reported no pain.

A crowded "triptan" market is entered by El triptan. Given that the higher and more effective dose of El triptan was not approved out of concern about side effects, it does not appear to offer any clinical advantages over currently available "triptans."

El triptan must be avoided for at least 72 hours after taking any powerful CYP3A4 inhibitors because CYP3A4 is the enzyme responsible for metabolizing the drug. They include ritonavir, nelfinavir, nefazodone, trope antimycin, ketoconazole, and itraconazole.

El triptan is thought to lessen brain-circumfusing blood vessel enlargement. The head discomfort of a migraine attack goes hand in hand with this swelling.

El triptan reduces pain and other symptoms including nausea and sensitivity to light and sound by preventing the release of chemicals from nerve endings that cause these symptoms. These actions are believed to aid in the symptom alleviation provided by eletriptan.

ELETRIPTAN MARKET COMPANY PROFILE

• Ajanta Pharma 
• Pfizer Inc.
• Manus Aktteva Biopharma LLP
• Anant Pharmaceuticals Pvt Ltd
• Trade India 

THIS ELETRIPTAN MARKET REPORT WILL ANSWER FOLLOWING QUESTIONS

1. How many El triptan are manufactured per annum globally? Who are the sub-component suppliers in different regions?
2. Cost breakup of a Global El triptan and key vendor selection criteria
3. Where is the El triptan manufactured? What is the average margin per unit?
4. Market share of Global El triptan market manufacturers and their upcoming products
5. Cost advantage for OEMs who manufacture Global El triptan in-house
6. key predictions for next 5 years in Global El triptan market
7. Average B-2-B El triptan market price in all segments
8. Latest trends in El triptan market, by every market segment
9. The market size (both volume and value) of the El triptan market in 2024-2030 and every year in between?
10. Production breakup of El triptan market, by suppliers and their OEM relationship